Enliven Therapeutics, Inc. (ELVN) stock intrinsic value fair value estimate & owner earnings analysis

Enliven Therapeutics is a clinical-stage cancer drug developer with no products for sale and no revenue. Its lead candidate, ELVN-001, is being tested in chronic myeloid leukemia (CML) in the Phase 1 ENABLE trial and received Orphan Drug Designation in November 2024. The company plans to start ENABLE-2, a pivotal Phase 3 trial in patients who have already had at least one prior treatment, in the second half of 2026. It also has a second candidate, ELVN-002. Because there are no sales, the business has no earnings to capitalize. Owner earnings, meaning operating cash flow after removing working-capital swings, stock compensation and equipment spending, have been negative every year we could measure: about -$2.13 per share in 2023, -$1.89 in 2024 and -$1.82 in 2025. Stock compensation is a large part of that ($34.0 million in 2025, up from $20.2 million in 2024), and we treat it as a real cost. Earlier years predate the February 2023 merger that created the current company and are not used. Our approach: a drug that has not been approved is not credited with any value, however promising the early data. Approval, a launch and future sales have not happened, so the value of the shares is the cash the company holds, less what it is likely to spend before the Phase 3 program reports. At June 30, 2026 the company held $895.2 million in cash and securities, about $13.52 per share on roughly 66.2 million diluted shares. The annual report said $462.6 million at the end of 2025 would fund operations into the first half of 2029, which implies planned spending of about $136 million a year; the balance has since nearly doubled even though the company kept spending, which means it raised a substantial amount of new capital in 2026. We did not review the terms of that financing, so if new shares were issued late in the second quarter, the share count we use may be somewhat low and the per-share values somewhat high. Actual operating cash burn was $70.3 million in 2025 and $37.8 million in the first half of 2026 (about $76 million annualized). We assume spending runs for three and a half years, to mid-2029, and that stock compensation continues at about $43 million a year (the first-half 2026 pace, annualized). Future cash flows are discounted at 6%. No value is assumed after that point. Bear case, $5.20 per share: spending follows the plan implied by the annual report ($136 million a year plus stock compensation), the Phase 3 program does not produce a marketable drug, and roughly $344 million of the cash is left when it ends. Base case, $6.59 per share: spending lands midway between the plan and the recent actual burn (about $106 million a year plus stock compensation), leaving about $436 million. Bull case, $7.99 per share: spending stays at the recent actual pace of about $76 million a year plus stock compensation, leaving about $529 million. Actual burn in 2025 and early 2026 has run well below the spending the annual report's runway implies, which is the evidence behind this case. None of the cases credits a drug approval, because none is yet secured. This is a deliberately cautious view: an approval of ELVN-001 would be worth far more than the cash, but we cannot point to evidence today that puts it in hand. What could make this wrong: a successful ENABLE-2 trial and approval would make the shares worth much more than any case here; a failed trial with heavier spending than planned would make them worth less. Further share sales to fund the trials would dilute existing holders. The company does not carry a going-concern warning; its annual report says the cash covers at least the next 12 months. Reconciliation note: our operating-cash figure differs from net loss mainly by non-cash stock compensation (net loss was $103.7 million in 2025 against a cash burn of $70.3 million).